Patents by Inventor Gudrun Reddersen

Gudrun Reddersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7550451
    Abstract: The invention relates to new compounds of general formula I, their production and pharmaceutical preparations that contain these compounds. The compounds according to the invention are preferably used for female birth control and for HRT.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: June 23, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Alexander Hillisch, Walter Elger, Gerd Schubert, Birgitt Schneider, Gudrun Reddersen
  • Patent number: 7534780
    Abstract: The invention relates to estradiol prodrugs of general formula (I), in which group Z is bonded to the steroid, process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with estrogenic action.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: May 19, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ralf Wyrwa, Sven Ring, Peter Droescher, Alexander Hillisch, Walter Elger, Birgitt Schneider, Gudrun Reddersen
  • Publication number: 20070197488
    Abstract: This invention provides prodrugs of 8?-substituted estratrienes of general formula (I), in which the group Z is bonded to the steroid, process for their production, pharmaceutical compositions that contain these compounds as well as use thereof. The compounds of general formula I according to the invention do not bind to the estrogen receptor ? and/or ?. They bind to carbonic anhydrases and inhibit these enzymes.
    Type: Application
    Filed: November 29, 2006
    Publication date: August 23, 2007
    Inventors: Olaf Peters, Gudrun Reddersen, Ralf Wyrwa, Alexander Hillisch, Walter Elger, Katja Prelle, Peter Droescher
  • Patent number: 7199115
    Abstract: New 17?-fluorosteroid compounds of formula (I) are disclosed: wherein R1 denotes H or methyl; R2 and R3 each denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring system respectively. These compounds have an activity profile with hybrid character so that they act as inhibitors for 5?-reductase and as high potency gestagens. Pharmaceutical compositions containing them are disclosed. They are suitable for treatment of conditions, which are caused by high levels of androgen in organs and tissues. These new compounds can be used in combination with other hormonal substances, such as estrogens, testosterone and other androgens, as contraceptives and for other applications.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: April 3, 2007
    Assignee: Schering AG
    Inventors: Ulrich Bothe, Peter Droescher, Walter Elger, Gudrun Reddersen, Bernd Menzenbach, Hans-Udo Schweikert, Alexander Hillisch, Birgitt Schneider
  • Patent number: 7053077
    Abstract: The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens, preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate, estradiol sulfamate or an N-acyl sulfamate of estrone, estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: May 30, 2006
    Assignee: Schering AG
    Inventors: Walter Elger, Pekka Lähteenmäki, Matti Lehtinen, Gudrun Reddersen, Holger Zimmermann, Michael Oettel, Sigfrid Schwarz
  • Publication number: 20050288267
    Abstract: The invention relates to estradiol prodrugs of general formula (I), in which group Z is bonded to the steroid, process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with estrogenic action.
    Type: Application
    Filed: May 20, 2005
    Publication date: December 29, 2005
    Inventors: Ralf Wyrwa, Sven Ring, Peter Droescher, Alexander Hillisch, Walter Elger, Birgitt Schneider, Gudrun Reddersen
  • Publication number: 20050282793
    Abstract: This invention relates to steroid prodrugs with androgenic action of general formula (I), in which group Z is bonded to the steroid, pharmaceutical compositions that contain these compounds as well as their use for the production of pharmaceutical agents with androgenic action.
    Type: Application
    Filed: May 23, 2005
    Publication date: December 22, 2005
    Inventors: Ralf Wyrwa, Sven Ring, Peter Droescher, Alexander Hillisch, Walter Elger, Birgitt Schneider, Gudrun Reddersen
  • Publication number: 20050277625
    Abstract: This invention provides estriol and estetrol prodrugs of general formula (I), in which group Y is bonded to the steroid process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with estrogenic action.
    Type: Application
    Filed: May 23, 2005
    Publication date: December 15, 2005
    Inventors: Ralf Wyrwa, Sven Ring, Peter Droescher, Alexander Hillisch, Walter Elger, Birgitt Schneider, Gudrun Reddersen
  • Publication number: 20050234027
    Abstract: New 17?-fluorosteroid compounds of formula (I) are disclosed: wherein R1 denotes H or methyl; R2 and R3 each denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring system respectively. These compounds have an activity profile with hybrid character so that they act as inhibitors for 5?-reductase and as high potency gestagens. Pharmaceutical compositions containing them are disclosed. They are suitable for treatment of conditions, which are caused by high levels of androgen in organs and tissues. These new compounds can be used in combination with other hormonal substances, such as estrogens, testosterone and other androgens, as contraceptives and for other applications.
    Type: Application
    Filed: April 13, 2005
    Publication date: October 20, 2005
    Inventors: Ulrich Bothe, Peter Droescher, Walter Elger, Gudrun Reddersen, Bernd Menzenbach, Hans-Udo Schweikert, Alexander Hillisch, Birgett Schneider
  • Publication number: 20050026891
    Abstract: The invention relates to new compounds of general formula I, their production and pharmaceutical preparations that contain these compounds. The compounds according to the invention are preferably used for female birth control and for HRT.
    Type: Application
    Filed: August 1, 2003
    Publication date: February 3, 2005
    Inventors: Alexander Hillisch, Walter Elger, Gerd Schubert, Birgitt Schneider, Gudrun Reddersen
  • Patent number: 6841548
    Abstract: The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formula R—SO2—O— at their C3 position wherein R is a R1R2N group wherein R1 and R2 are independent of each other and represent a hydrogen atom, a C1-C5 alkyl radical or, together with the N atom, a polymethylene imino radical containing 4 to 6 C atoms, or a morpholino radical. The preparations according to the invention can be used for hormonal contraception and for hormon replacement therapy (HRT). They exhibit a low hepatic estrogenity.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: January 11, 2005
    Assignee: Schering AG
    Inventors: Sigfrid Schwarz, Walter Elger, Christel Siemann, Gudrun Reddersen, Birgitt Schneider, Hans-Joachim Siemann
  • Publication number: 20040067923
    Abstract: The invention relates to the use of mono-sulfamate prodrugs of estriol, such as estriol-3-sulfamate, for the treatment of autoimmune diseases, such as multiple sclerosis (MS).
    Type: Application
    Filed: February 27, 2003
    Publication date: April 8, 2004
    Inventors: Walter Elger, Gudrun Reddersen, Birgitt Schneider, Harald Von Keyserlingk, Frank Dahlke, Sigfrid Schwarz
  • Publication number: 20030130249
    Abstract: This invention describes the use of estrogen receptor (ER)&bgr;-selective agonists for the production of a pharmaceutical agent for triggering somatotropic and/or organotropic effects in the CNS, the circulatory system, the skeletal system and/or the immune system in the aging male and female organism (anticatabolic therapy).
    Type: Application
    Filed: October 17, 2002
    Publication date: July 10, 2003
    Applicant: Schering AG
    Inventors: Walter Elger, Gudrun Reddersen, Birgitt Schneider, Alexander Hillisch, Olaf Peters, Dirk Kosemund, Gerd Muller
  • Patent number: 6583130
    Abstract: The invention relates to new C13-substituted estra-1,3,5(10)-trien-3-yl sulfamates of general formula I, wherein R1 represents an acyl residue, oxycarbonyl residue, aminocarbonyl residue, sulfonyl residue, or aminosulfonyl residue, and R15 represents ethyl, methods of preparing same, and pharmaceutical compositions containing these compounds. The compounds of the invention of general formula I inhibit the activity of steroid sulfatase (EC 3.1.6.2) and do not exhibit any estrogenic effect.
    Type: Grant
    Filed: September 6, 2000
    Date of Patent: June 24, 2003
    Assignee: Schering AG
    Inventors: Sigfrid Schwarz, Gerd Müller, Dirk Kosemund, Margit Richter, Olaf Peters, Ina Scherlitz-Hofmann, Thomas Michel, Walter Elger, Gudrun Reddersen, Birgitt Schneider
  • Patent number: 6569844
    Abstract: The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formula R—SO2—O— at their C3 position wherein R is a R1R2N group wherein R1 and R2 are independent of each other and represent a hydrogen atom, a C1-C5 alkyl radical or, together with the N atom, a polymethylene imino radical containing 4 to 6 C atoms, or a morpholino radical. The preparations according to the invention can be used for hormonal contraception and for hormon replacement therapy (HRT). They exhibit a low hepatic estrogenity.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: May 27, 2003
    Assignee: Jenapharm GmbH & Co., KG
    Inventors: Sigfrid Schwarz, Walter Elger, Hans-Joachim Siemann, Gudrun Reddersen, Birgitt Schneider
  • Publication number: 20020193444
    Abstract: There is provided a pharmaceutical composition comprising (i) a compound of the formula 1
    Type: Application
    Filed: April 10, 2002
    Publication date: December 19, 2002
    Inventors: Barry Victor Lloyd Potter, Michael John Reed, Walter Elger, Gudrun Reddersen, Heinrich-Thomas Proske
  • Publication number: 20020061868
    Abstract: The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formula
    Type: Application
    Filed: November 21, 2001
    Publication date: May 23, 2002
    Inventors: Sigfrid Schwarz, Walter Elger, Christel Siemann, Gudrun Reddersen, Birgitt Schneider
  • Publication number: 20010021707
    Abstract: There is provided a pharmaceutical composition comprising (i) a compound of the formula 1
    Type: Application
    Filed: January 5, 2001
    Publication date: September 13, 2001
    Inventors: Barry Victor Lloyd Potter, Michael John Reed, Walter Elger, Gudrun Reddersen, Heinrich-Thomas Proske
  • Patent number: 6080735
    Abstract: This invention is relating to new estra-1,3,5(10)-trien-sulfamates carrying at the 3-position an R--SO.sub.2 --O--group, with R being an R.sup.1 R.sup.2 N--group in which R.sup.1 and R.sup.2, independently of each other, represent a hydrogen atom, an alkyl residue with 1-5 C atoms or, together with the N atom, a polymethylene-imino residue with 4-6 C atoms or a morpholino residue.The compounds, according to this invention, are suitable for hormonal contraception and climacteric hormone replacement therapy (HRT) as well as for treatment of gynecological and andrological diseases. Hence, only low hepatic estrogenicity is exhibited by the compounds according to this invention.Also described are processes for preparation of the compounds according to this invention and for preparation of pharmaceutical compositions.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: June 27, 2000
    Assignee: Jenapharm GmbH & Co. KG
    Inventors: Sigfrid Schwarz, Walter Elger, Hans-Joachim Siemann, deceased, by Margit Lucas, heir, by Frank Siemann, heir, Gudrun Reddersen, Birgitt Schneider
  • Patent number: 5705495
    Abstract: The invention relates to new sulfamate derivatives of 1,3,5(10)-estratriene derivatives of the general formula I ##STR1## wherein the 3-sulfamate moiety is acylated, sulfonated or amidosulfonated. Furthermore, methods for the production of the compound and pharmaceutical preparations containing this compound are described. The compounds according to the invention have an estrogenic effect.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: January 6, 1998
    Assignee: Jenapharm GmbH & Co. KG.
    Inventors: Sigfrid Schwarz, Walter Elger, Gudrun Reddersen, Birgitt Schneider, Ina Thieme, Margit Richter